[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20150271A - Peptidos como agonistas de oxitocina - Google Patents

Peptidos como agonistas de oxitocina

Info

Publication number
CR20150271A
CR20150271A CR20150271A CR20150271A CR20150271A CR 20150271 A CR20150271 A CR 20150271A CR 20150271 A CR20150271 A CR 20150271A CR 20150271 A CR20150271 A CR 20150271A CR 20150271 A CR20150271 A CR 20150271A
Authority
CR
Costa Rica
Prior art keywords
oxychocine
agonists
peptides
compounds
formula
Prior art date
Application number
CR20150271A
Other languages
English (en)
Inventor
Caterina Bissantz
Konrad Bleicher
Christophe Grundschober
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20150271A publication Critical patent/CR20150271A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula I.
CR20150271A 2012-12-21 2015-05-21 Peptidos como agonistas de oxitocina CR20150271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12199012 2012-12-21
PCT/EP2013/076783 WO2014095773A1 (en) 2012-12-21 2013-12-17 Peptides as oxytocin agonists

Publications (1)

Publication Number Publication Date
CR20150271A true CR20150271A (es) 2015-08-28

Family

ID=47471593

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150271A CR20150271A (es) 2012-12-21 2015-05-21 Peptidos como agonistas de oxitocina

Country Status (34)

Country Link
US (1) US9868766B2 (es)
EP (1) EP2935312B1 (es)
JP (1) JP6067878B2 (es)
KR (1) KR101819804B1 (es)
CN (1) CN104870466B (es)
AR (1) AR094225A1 (es)
AU (1) AU2013363768B2 (es)
BR (1) BR112015014010A2 (es)
CA (1) CA2895150C (es)
CL (1) CL2015001724A1 (es)
CR (1) CR20150271A (es)
DK (1) DK2935312T3 (es)
EA (1) EA026687B1 (es)
ES (1) ES2690317T3 (es)
HK (1) HK1208477A1 (es)
HR (1) HRP20181569T1 (es)
HU (1) HUE039848T2 (es)
IL (1) IL239519A (es)
LT (1) LT2935312T (es)
MA (1) MA38272A1 (es)
MX (1) MX358684B (es)
MY (1) MY176398A (es)
NZ (1) NZ708175A (es)
PE (1) PE20151446A1 (es)
PH (1) PH12015501145B1 (es)
PL (1) PL2935312T3 (es)
PT (1) PT2935312T (es)
RS (1) RS57690B1 (es)
SG (1) SG11201504883PA (es)
SI (1) SI2935312T1 (es)
TW (1) TWI558726B (es)
UA (1) UA119034C2 (es)
WO (1) WO2014095773A1 (es)
ZA (1) ZA201504186B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
EP2935303B1 (en) 2012-12-21 2021-02-17 Janssen BioPharma, Inc. 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
MX358684B (es) 2012-12-21 2018-08-31 Hoffmann La Roche Peptidos como agonistas de oxitocina.
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
KR102116107B1 (ko) 2013-12-30 2020-05-28 삼성디스플레이 주식회사 표시 장치
WO2015106200A2 (en) 2014-01-10 2015-07-16 Cornell University Dipeptides as inhibitors of human immunoproteasomes
SG11201610073PA (en) 2014-06-03 2016-12-29 Hoffmann La Roche Peptides as oxytocin agonists
EA031892B1 (ru) 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MX369345B (es) * 2014-08-07 2019-11-06 Hoffmann La Roche Procesos para la preparacion de analogos de oxitocina.
EP3193904A4 (en) * 2014-08-18 2018-04-11 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
FI3666258T3 (fi) * 2014-09-19 2024-02-09 Ferring Bv Menetelmä prader-willin oireyhtymän hoitamiseksi
ES2905008T3 (es) 2015-10-15 2022-04-06 Univ Cornell Inhibidores de proteasomas y usos de los mismos
EP3694605A4 (en) 2017-10-11 2021-10-27 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
TW202031283A (zh) 2018-09-20 2020-09-01 馬克 C 曼寧 穩定卡貝縮宮素鼻內製劑
WO2021126990A1 (en) * 2019-12-16 2021-06-24 The Scripps Research Institute Oxytocin derivatives with improved properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539310B2 (ja) 2008-03-31 2014-07-02 フェリング ベスローテン フェンノートシャップ オキシトシン類似体
TWI463990B (zh) 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
WO2011038451A1 (en) * 2009-10-01 2011-04-07 The University Of Sydney Therapy and prevention of problem drinking
MX358684B (es) 2012-12-21 2018-08-31 Hoffmann La Roche Peptidos como agonistas de oxitocina.

Also Published As

Publication number Publication date
HUE039848T2 (hu) 2019-02-28
KR20150085845A (ko) 2015-07-24
HRP20181569T1 (hr) 2018-11-30
MA38272A1 (fr) 2017-07-31
ES2690317T3 (es) 2018-11-20
AU2013363768B2 (en) 2016-02-04
EA026687B1 (ru) 2017-05-31
AU2013363768A1 (en) 2015-06-04
PH12015501145A1 (en) 2015-08-10
BR112015014010A2 (pt) 2017-07-11
MX358684B (es) 2018-08-31
EP2935312A1 (en) 2015-10-28
CN104870466B (zh) 2018-05-18
SI2935312T1 (sl) 2018-11-30
IL239519A0 (en) 2015-08-31
HK1208477A1 (en) 2016-03-04
CN104870466A (zh) 2015-08-26
US9868766B2 (en) 2018-01-16
LT2935312T (lt) 2018-10-25
RS57690B1 (sr) 2018-11-30
ZA201504186B (en) 2016-04-28
TWI558726B (zh) 2016-11-21
PH12015501145B1 (en) 2015-08-10
EP2935312B1 (en) 2018-08-08
EA201591078A1 (ru) 2015-10-30
JP6067878B2 (ja) 2017-01-25
JP2016503044A (ja) 2016-02-01
KR101819804B1 (ko) 2018-01-17
DK2935312T3 (en) 2018-10-22
NZ708175A (en) 2020-06-26
PT2935312T (pt) 2018-10-26
UA119034C2 (uk) 2019-04-25
CA2895150C (en) 2019-11-26
CA2895150A1 (en) 2014-06-26
TW201429994A (zh) 2014-08-01
WO2014095773A1 (en) 2014-06-26
PE20151446A1 (es) 2015-09-28
PL2935312T3 (pl) 2018-12-31
MX2015007365A (es) 2015-10-14
AR094225A1 (es) 2015-07-22
US20150284434A1 (en) 2015-10-08
CL2015001724A1 (es) 2015-10-16
IL239519A (en) 2017-06-29
SG11201504883PA (en) 2015-07-30
MY176398A (en) 2020-08-05

Similar Documents

Publication Publication Date Title
CR20150271A (es) Peptidos como agonistas de oxitocina
JOP20180102B1 (ar) مركب صيدلاني
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CR20140463A (es) Compuestos de heterociclilo como inhibidores de mek
CR20140510A (es) Nucleósidos de espirooxetano de uracilo
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
CO7151548A2 (es) Picolinamidas macrocíclicas como fungicidas
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UY34092A (es) Nuevos compuestos como inhibidores de jak
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34798A (es) Polipéptidos de unión a receptores de quimiocinas
UY34523A (es) Derivados de betulina
UY34591A (es) Compuestos de imidazopirrolidinona
UY34654A (es) Inhibidores de la beta-secretasa
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
CR20140535A (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
UY34550A (es) Bencilpirazoles sustituidos
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY34146A (es) Compuestos inhibidores de metaloenzimas
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
ES2643056T3 (es) Piridina-2-amidas útiles como agonistas de cb2
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY34817A (es) Tienopirimidinas
CR20130539A (es) Triazolopiridinas